Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-024-07018-9 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Rahel H Wallimann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research, Novartis, Basel, 4056, Switzerland. Hauptthemen laut MEDLINE: Lanthanoid Series Elements, Mass Spectrometry, Radiopharmaceuticals. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PSI - Paul Scherrer Institute.
Abstract (Originalsprache)
Purpose
With the growing interest in exploring radiolanthanides for nuclear medicine applications, the question arises as to whether they are generally interchangeable without affecting a biomolecule’s pharmacokinetic properties. The goal of this study was to investigate similarities and differences of four (radio)lanthanides simultaneously applied as complexes of biomolecules or in ionic form.
Methods
Inductively coupled plasma mass spectrometry (ICP-MS) was employed for the simultaneous detection of four lanthanides (Ln = lutetium, terbium, gadolinium and europium) in biological samples. In vitro tumor cell uptake and in vivo biodistribution studies were performed with Ln-DOTATATE, Ln-DOTA-LM3, Ln-PSMA-617 and Ln-OxFol-1. AR42J cells, PC-3 PIP cells and KB cells expressing the somatostatin receptor, the prostate-specific membrane antigen and the folate receptor, respectively, were used in vitro as well as to obtain the respective tumor mouse models for in vivo studies. The distribution of lanthanides in ionic form was investigated in immunocompetent mice. Dual-isotope SPECT/CT imaging studies were performed with mice administered with the radiolabeled biomolecules or chloride salts of lutetium-177 and terbium-161.
Results
Similar in vitro cell uptake was observed for all four lanthanide complexes of each biomolecule into the respective tumor cell lines. AR42J tumor uptake of Ln-DOTATATE and Ln-DOTA-LM3 in mice showed similar values for all lanthanide complexes (3.8‒5.1% ID/g and 4.5‒5.0% ID/g; 1 h p.i., respectively). Accumulation of Ln-PSMA-617 in PC-3 PIP tumors (24–25% ID/g; 1 h p.i.) and of Ln-OxFol-1 in KB tumors (28–31% ID/g; 24 h p.i.) were also equal for the four lanthanide complexes of each biomolecule. After injection of lanthanide chloride salts (LnCl 3 ; Ln = nat Lu, nat Tb, nat Gd, nat Eu), the liver uptake was different for each metal (~ 12% ID/g, ~ 22% ID/g, ~ 31% ID/g and ~ 37% ID/g; 24 h p.i., respectively) which could be ascribed to the radii of the respective lanthanide ions. In the bones, accumulation was considerably higher for lutetium than for other lanthanides (25 ± 5% ID/g vs. 14‒15% ID/g; 24 h p.i.). These data were confirmed visually by 177 Lu/ 161 Tb-based dual-isotope SPECT/CT images.
Conclusions
The presented study confirmed similar properties of Ln-complexes, suggesting that lutetium-177 can be replaced by other radiolanthanides, most probably without affecting the tissue distribution profile of the resultant radiopharmaceuticals. On the other hand, the different radii of the lanthanide ions affected their uptake and resorption mechanisms in liver and bones when injected in uncomplexed form.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Research, Novartis, Basel, 4056, Switzerland.
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland.
- Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, 5232, Switzerland.
- Institut Laue-Langevin, Grenoble, 38042, France.
- Laboratory of Radiochemistry, PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, 5232, Switzerland.
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland. cristina.mueller@psi.ch.
ORCID-Profile: Cristina Müller
Förderung
- PSI - Paul Scherrer Institute
Zitieren
APA
Wallimann, R. H., Mehta, A., Mapanao, A. K., Köster, U., Kneuer, R., Schindler, P., van der Meulen, N. P., Schibli, R., & Müller, C. (2025). Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-07018-9
Vancouver
Wallimann RH, Mehta A, Mapanao AK, Köster U, Kneuer R, Schindler P, et al. Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-07018-9
BibTeX
@article{Wallimann2025,
author = {Wallimann, Rahel H and Mehta, Avni and Mapanao, Ana Katrina and Köster, Ulli and Kneuer, Rainer and Schindler, Patrick and van der Meulen, Nicholas P and Schibli, Roger and Müller, Cristina},
title = {Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-024-07018-9}
}
EUVIMED